Indivior legal costs rise, new anti-addiction drug ready

LONDON (Reuters) - Britain's Indivior, which makes drugs to treat opioid addiction and plans to launch a key new product this month, said on Thursday it had increased provisions for investigative and antitrust litigation matters to $438 million.